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SUMMARY – Over the past decade, intravitreal injections of anti-VEGF agents have been wide-
ly used and intensively developed as a treatment option for many ophthalmological indications. Due 
to its availability and low cost, the most frequently used anti-VEGF agent is bevacizumab. Th is type 
of therapy is often indicated in patients with exudative age-related macular degeneration (ARMD) 
and diabetic macular edema (DME). If, in addition to these two conditions, patients have a diagnosis 
of primary open angle glaucoma (POAG), they also present with optic nerve head (ONH) retinal 
nerve fi ber layer (RNFL) thinning. Th e aim of this prospective study was to establish whether admin-
istering bevacizumab to patients with POAG leads to additional reduction of RNFL thickness. Th e 
study included 60 patients divided into two groups. First group comprised the eyes of patients with 
exudative ARMD and POAG, whereas second group comprised the eyes of patients with DME and 
POAG, all treated with bevacizumab. Control group comprised the fellow eye of each involved pa-
tient, which was not treated with bevacizumab. In a period of one year, all patients underwent optical 
coherence tomography (OCT) measurements of ONH RNFL thickness. Th e results of all patients 
were compared between the two study groups and then with control group results. Study results 
showed a decrease of RNFL in both groups of patients. Comparison of these two groups of patients 
after one year revealed a statistically more signifi cant decrease in RNFL thickness in the second group 
(DME + POAG).
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Introduction
Intravitreal injections of anti-vasoendothelial 
growth factor (anti-VEGF) agents have become one 
of the most advanced ophthalmological treatment op-
tions over the past ten years. Anti-VEGF agents are 
used for various ophthalmological disorders, including 
exudative form of age-related macular degeneration 
(ARMD)1, diabetic retinopathy and diabetic macular 
edema (DME)2, retinopathy of prematurity3,4, central 
and branch retinal vein occlusion5, neovascular glau-
coma, tumors6, etc. Th ere are various anti-VEGF med-
ications available on the market, bevacizumab (Avas-
tin, Genentech, San Francisco, USA) being the pre-
dominant one in Croatia. Bevacizumab is a humanized 
recombinant monoclonal IgG antibody that binds and 
inhibits all VEGF-A isoforms. Originally approved 
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for the treatment of colorectal carcinoma, bevacizum-
ab is used in ophthalmology as an off -label medication 
for intravitreal administration with favorable results in 
clinical practice. Anti-VEGF agents bind and block 
VEGF on the surface of various blood and lymphatic 
vessels. VEGF is secreted in response to ischemia and 
is responsible for inducing angiogenesis and neovascu-
larization. Th ere are two types of macular degenera-
tion, i.e. dry or non-exudative form, characterized by 
the presence of drusen and geographic atrophy7, and 
wet or exudative form, characterized by the presence of 
choroidal neovascularizations.
Th e wet or exudative form of ARMD is one of the 
most common indications for intravitreal administra-
tion of bevacizumab. Th e patients frequently complain 
of a sudden onset of signifi cantly decreased visual acu-
ity. Later stages of this disorder include cicatrization 
(scar formation) of the aff ected macular area, which 
leads to permanent loss of central visual acuity. In the 
absence of any other eye disorders, the patient’s pe-
ripheral sight remains undamaged. Senile macular de-
generation is diagnosed by performing ophthalmo-
scopic examination via optical coherence tomography 
(OCT), OCT angiography, and at times, fl uorescein 
angiography8,9.
Diabetic macular edema most often accompanies 
diabetic retinopathy and is one of the most common 
diabetes-related eye complications. DME is also 
 diagnosed by performing ophthalmoscopic exa-
mination via OCT, OCT-A and fl uorescein angio-
graphy8.
Primary open angle glaucoma (POAG) is a chron-
ic optic neuropathy, which, if left untreated, leads to a 
decreased retinal nerve fi ber layer (RNFL) thickness, 
as well as peripheral and subsequently central visual 
fi eld loss. To make an accurate diagnosis, and also to 
confi rm disease progression, it is important to perform 
regular measurements of optic nerve head (ONH) 
RNFL thickness with OCT scans, as well as regular 
computerized automated perimetry8.
Patients suff ering from POAG who are diagnosed 
with exudative ARMD or DME are at a risk of losing 
central visual acuity and peripheral vision. Th e aim 
of this study was to establish whether intravitreal 
 administration of bevacizumab leads to additional 
 decrease in RNFL thickness in patients already 
 diagnosed with POAG and decreased thickness of 
ONH RNFL.
Subjects and Methods
Sixty patients over the age of 18, both male and 
female, were enrolled in this prospective study and 
 divided into two groups. Due to their primary disor-
der, all of these patients would have been treated with 
intravitreal bevacizumab regardless of the study. Th e 
fi rst group comprised 30 eyes of patients suff ering 
from exudative ARMD and POAG. Th e second group 
comprised 30 eyes of patients suff ering from DME 
and POAG. All eyes included in this study received a 
minimum of 4 intravitreal bevacizumab injections over 
the course of 12 months.
Control group comprised the fellow eye of each in-
volved patient, also diagnosed with POAG, but not 
treated with bevacizumab prior to or during the study. 
Each subject received a participant information sheet, 
as well as a special form containing information on the 
type of therapy, medical procedure to be performed, 
general risks of the procedure, success rates and guide-
lines for early post-administration period, which is 
routinely handed out to every patient scheduled for 
bevacizumab injections at our Department. Each sub-
ject was given the approval issued by the Medicines 
Committee of the Osijek University Hospital Center 
concerning the administration described.
All subjects underwent OCT scanning and mea-
surement of the mean and per quadrant (temporal, na-
sal, inferior and superior) ONH RNFL thickness 
(Copernicus HR, Optopol, Zawiercie, Poland) prior to 
the administration of bevacizumab, and then at 1, 3, 6 
and 12 months following the administration of beva-
cizumab. During this time, each subject received a 
minimum of four intravitreal bevacizumab doses. For 
the purpose of this examination, mydriasis was 
achieved by applying 1 drop of tropicamide and 1 drop 
of phenylephrine hydrochloride to the eye.
As part of primary disorder treatment, all subjects 
received intravitreal injections of 1.25 mg bevacizum-
ab (Avastin, Genentech, San Francisco, USA) at least 
four times or more, at intervals of 4 to 6 weeks. Intra-
vitreal injections were administered in sterile environ-
ment of an operating room, always by the same oph-
thalmologist.
Each group of subjects included a control group, 
which comprised the fellow eye of each involved pa-
tient, which was not injected with bevacizumab. Each 
measurement included both eyes.
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Patients with other ocular pathologies, such as ad-
vanced cataract stage, glaucoma patients with poorly 
regulated intraocular pressure (IOP), patients with 
amblyopia, glaucoma patients with a cup to disc ratio 
over 0.8, patients with reduced corneal transparency, 
patients with blurred vitreous body, patients who un-
derwent retinal laser photocoagulation, vitrectomized 
patients and patients who had to receive anti-VEGF 
agents in both eyes prior to or during this study due to 
their primary disorder were excluded.
Statistical analysis
Both descriptive and inferential statistics were used 
on data analysis. Dependent samples t-test was used to 
establish signifi cance of variations in nerve fi ber thick-
ness within the same patient group at the beginning of 
treatment and 12 months after the treatment. Inde-
pendent samples t-test was used to analyze variations 
in the mean nerve fi ber thickness in the patients’ dis-
eased eyes (experimental group) and control eyes (con-
trol group). Th e mean values of nerve fi ber thickness 
with 95% confi dence intervals were presented graphi-
cally. All variations with p<0.05 were considered to be 
statistically signifi cant.
Results
Th e study enrolled 60 subjects divided into two 
groups. First group enrolled 30 patients diagnosed 
with exudative form of ARMD and POAG, 12 male 
and 18 female, mean age 67.37(±11.93) years. Th ey re-
ceived a mean of 6.27 bevacizumab injections intravit-
really in the treated eye during the 12-month period. 
Second group of patients included 30 patients diag-
nosed with DME and POAG, 13 male and 17 female, 
mean age 64.5(±11.22) years. Patients enrolled in this 
group were treated with a mean of 6.5 bevacizumab 
injections during the 12-month follow up period.
In the fi rst group of patients (ARMD + POAG), 
RNFL thickness decreased during 12 months from 
77.27 μm (±12.48) to 76.20 μm (±12.53), mean 1.07 
μm, on the treated eye (Table 1). Analysis of the fellow 
eye showed that RNFL decreased during 12 months 
from 76.46 μm (±16.40) to 75.03 μm (±16.39), mean 
1.43 μm (Table 1). Comparison of the treated and fel-
low eyes yielded no statistically signifi cant diff erence 
in RNFL thickness decrease between the two groups 
of eyes (Table 1, Fig. 1). RNFL thickness measured in 
the quadrants of treated eyes also decreased statisti-
cally signifi cantly, which was most pronounced in 
temporal (T) quadrant, -1.13 μm, and least in nasal 

















*Statistically signifi cant at the level p<0.05; ARMD + POAG = age-related macular degeneration + primary open angle glaucoma
RNFL = retinal nerve fi ber layer; ARMD + POAG = age-related 
macular degeneration + primary open angle glaucoma
Fig. 1. Arithmetic means of RNFL (ARMD + POAG) 
in injected and noninjected eyes with 95% confi dence 
intervals at the beginning and after 12 months.
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(N) quadrant, -0.37 μm (Table 2). At 12 months, the 
group of fellow eyes also showed a statistically signifi -
cant decrease in RNFL thickness according to quad-
rants. Th e greatest decrease in RNFL thickness was 
recorded in temporal (T) quadrant, -1.00 μm, and the 
least in nasal (N) quadrant, -0.50 μm (Table 3). Com-
parison of the treated and fellow eyes in this group of 
patients yielded no statistically signifi cant diff erence 
in RNFL thickness decrease during the 12-month pe-
riod either.
In the second group of patients (DME + POAG), 
RNFL thickness decreased during 12 months from 
84.90 μm (±16.41) to 81.10 μm (±16.08), mean 3.80 
μm, on the treated eye (Table 4). In the fellow eye, 
RNFL decreased during 12 months from 92.30 μm 
(±13,60) to 90.03 μm (±13.52), mean 2.27 μm (Table 
4). Comparison of the treated and fellow eyes yielded 
a statistically signifi cant diff erence in RNFL thickness 
decrease between these two groups of eyes (Table 4, 
Fig. 2). RNFL thickness measured in the quadrants of 
treated eyes also decreased statistically signifi cantly, 
which was most pronounced in inferior (I) quadrant, 
-3.46 μm, and least in nasal (N) quadrant, -1.37 μm 
(Table 5). At 12 months, the group of fellow eyes also 
showed a statistically signifi cant decrease in RNFL 
thickness according to quadrants. Th e greatest decrease 
in RNFL thickness was recorded in inferior (I) quad-
rant, -2.97 μm, and the least in nasal (N) quadrant, 
-0.83 μm (Table 6). Comparison of the treated and 
fellow eyes in this group of patients yielded no statisti-










Month 0 65.86 14.17
1.13 9.109 0.000*
Month 12 64.73 14.08
S
Month 0 92.10 17.64
0.43 3.612 0.001*
Month 12 91.73 17.71
N
Month 0 66.20 11.64
0.37 4.176 0.000*
Month 12 65.77 11.53
I
Month 0 93.33 18.88
1.06 7.443 0.000*
Month 12 92.27 18.83
*Statistically signifi cant at the level p<0.05; ARMD + POAG = age-related macular degeneration + primary open angle glaucoma; 
T = temporal; S = superior; N = nasal; I = inferior










Month 0 64.27 13.16
1.00 6.021 0.000*
Month 12 63.27 13.17
S
Month 0 92.36 19.60
0.53 2.719 0.011*
Month 12 91.83 19.43
N
Month 0 68.53 13.04
0.50 3.042 0.005*
Month 12 68.03 13.25
I
Month 0 91.57 23.43
0.90 5.137 0.000*
Month 12 90.67 23.34
*Statistically signifi cant at the level p<0.05; ARMD + POAG = age-related macular degeneration + primary open angle glaucoma; 
T = temporal; S = superior; N = nasal; I = inferior
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*Statistically signifi cant at the level p<0.05; DME + POAG = diabetic macular edema + primary open angle glaucoma
RNFL = retinal nerve fi ber layer; DME + POAG = diabetic macu-
lar edema + primary open angle glaucoma
Fig. 2. Arithmetic means of RNFL (DME + POAG) 
of injected and noninjected eyes with 95% confi dence 
intervals at the beginning and after 12 months.







Diff erence (μm) t p
T
Month 0 55.10 10.29
2.30 12.752 0.000*
Month 12 52.80 10.22
S
Month 0 98.63 22.69
1.73 7.901 0.000*
Month 12 96.90 22.48
N
Month 0 67.07 12.92
1.37 2.700 0.011*
Month 12 65.70 13.05
I
Month 0 95.73 20.13
3.46 12.268 0.000*
Month 12 92.27 20.05
*Statistically signifi cant at the level p<0.05; DME + POAG = diabetic macular edema + primary open angle glaucoma; T = temporal; 
S = superior; N = nasal; I = inferior
cally signifi cant diff erence in RNFL thickness de-
crease during 12-month period.
Discussion
With longer life expectancy, the number of patients 
diagnosed with ARMD is increasing. ARMD is the 
third cause of blindness in developed countries10. 
While no appropriate therapy has yet been found for 
the dry form of ARMD, the exudative or wet form of 
ARMD is successfully treated with intravitreal injec-
tions of anti-VEGF agents. DME is the most com-
mon cause of visual impairment in patients with dia-
betes mellitus11 and it is also treated with anti-VEGF 
agents. Numerous studies, experimental12 and clinical, 
investigated safety and possible side eff ects of intravit-
real anti-VEGF therapy, especially bevacizumab13-16.
When discussing RNFL thickness safety, previous 
studies showed that multiple intravitreal bevacizumab 
injections did not decrease RNFL thickness17-20. Clini-
cal studies mostly enrolled patients with ARMD21, 
whereas patients with other indications for intravitreal 
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anti-VEGF therapy were less frequently included20. 
Any kind of glaucoma disease in patients on anti-
VEGF therapy was an exclusion criterion for enrolling 
patients in all of these studies. Most researchers ex-
plain it with previously decreased RNFL thickness 
due to glaucomatous damage.
On designing this study, we were interested in as-
sessing the eff ect of multiple intravitreal bevacizumab 
injections on RNFL thickness in POAG patients. 
VEGF is known to be an angiogenic and neurotropic 
factor, therefore long-term suppression of neurotropic 
cytokines could theoretically explain additional RNFL 
thickness decrease in patients receiving anti-VEGF 
agents22,23. It is also known that intravitreal therapy can 
sometimes cause transient or sustained IOP eleva-
tion24-29. Th ese IOP spikes can be potentially danger-
ous for additional damage of RNFL in patients with 
POAG.
Results in the fi rst group of patients with ARMD 
and POAG showed that there was no signifi cant dif-
ference in the decrease of RNFL thickness between 
the injected and noninjected eyes during 12-month 
follow up period (p=0.758). Th ese results are consis-
tent with those reported from other similar studies, 
including electrophysiological30 and clinical studies, 
which could not demonstrate any toxic eff ect of intra-
vitreal bevacizumab on RNFL thickness. When we 
analyzed quadrant changes in RNFL thickness during 
12-month follow up, we found temporal quadrant to 
show greatest thinning and nasal quadrant smallest 
thinning. Both eye groups, injection and noninjection, 
showed the same pattern of RNFL thickness changes, 
without statistically signifi cant diff erence between 
them. Th e main limiting factor in this group was the 
relatively small number of patients enrolled due to the 
low prevalence of patients diagnosed with exudative 
form of ARMD and POAG.
In the second group of patients diagnosed with 
DME and POAG, 12-month follow up period showed 
a statistically signifi cant diff erence in overall RNFL 
thickness between the groups of injected and nonin-
jected eyes (p=0.023). Analysis of quadrant changes of 
RNFL yielded no statistically signifi cant diff erence at 
12-month follow up, with greatest change recorded in 
the inferior quadrant. Th ese results indicated that the 
eff ect of multiple intravitreal bevacizumab injections 
on RNFL thickness may have occurred in this group 
of patients. Comparison of these results with the fi rst 
group of patients (ARMD + POAG) revealed that the 
mean decrease of RNFL thickness was greater in this 
group, suggesting DME as part of diabetic retinopathy 
changes as another risk factor for RNFL thinning, i.e. 
inner retinal ischemia31-34. Th is group of patients had 
several limiting factors. As for the fi rst group, the 
number of enrolled patients was small because of all 
inclusion criteria and small prevalence of patients with 
these two diseases. In addition, this group of patients 
usually had initial diabetic macular changes on one 
eye, but with time they developed the same condition 
on the fellow eye and needed intravitreal treatment for 
the fellow eye too and that was the main reason why 
the follow up period was not longer.










Month 0 58.83 9.25
1.63 7.350 0.000*
Month 12 57.20 9.49
S
Month 0 108.60 17.04
1.43 6.738 0.000*
Month 12 107.17 17.31
N
Month 0 68.96 9.84
0.83 4.805 0.000*
Month 12 68.13 9.72
I
Month 0 105.00 20.09
2.97 2.423 0.000*
Month 12 102.03 19.87
*Statistically signifi cant at the level p<0.05; DME + POAG = diabetic macular edema + primary open angle glaucoma; T = temporal; 
S = superior; N = nasal; I = inferior
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Results of this prospective study show that we can-
not be sure that multiple intravitreal bevacizumab in-
jections are safe for RNFL thickness in all indications 
for which patients receive them. Patients with POAG 
and other types of glaucoma are at a particularly high 
risk because any additional RNFL thinning is danger-
ous and any IOP elevation, even at short terms, must 
be prevented. We should also keep in mind that some 
of the diseases that require chronic intravitreal bevaci-
zumab therapy, such as DME and retinal vein occlu-
sions, through inner retinal ischemia, additionally de-
crease RNFL thickness over time. It is necessary to 
conduct more studies of similar design with larger 
numbers of POAG patients and longer follow up pe-
riod to determine safety and possible infl uence of bev-
acizumab and other anti-VEGF agents on RNFL 
thickness.
In conclusion, our results showed a statistically sig-
nifi cant loss of retinal nerve fi bers in both groups of 
patients, i.e. those with ARMD + POAG and DME + 
POAG, during 12-month follow up. Considering that 
these patients already have compromised RNFL 
thickness, the possible changes of RNFL thickness 
caused by chronic bavacizumab injections are not neg-
ligible. Th us, it appears reasonable to monitor IOP el-
evations and RNFL thickness more closely during in-
travitreal treatment in patients with POAG and espe-
cially DME + POAG.
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Sažetak
DEBLJINA SLOJA ŽIVČANIH VLAKANA MREŽNICE U GLAUKOMSKIH BOLESNIKA 
LIJEČENIH MULTIPLIM INTRAVITREALNIM INJEKCIJAMA ANTI-VEGF-a (BEVACIZUMABA)
A. Kopić, D. Biuk, J. Barać, M. Vinković, T. Benašić i V. Kopić
Intravitrealna aplikacija anti-VEGF agenasa za različite indikacije jedna je od najprimjenjivanijih i najbrže razvijajućih 
terapijskih mogućnosti posljednih godina u oftalmologiji. Najčešće se zbog svoje dostupnosti i cijene koristi bevacizumab. 
Eksudativna senilna makularna degeneracija (SMD) i dijabetički makularni edem (DME) među najčešćim su indikacijama 
za ovu vrstu terapije. Ako uz ove dijagnoze bolesnici imaju i primarni glaukom otvorenog kuta (engl. primary open angle 
glaucoma, POAG), imaju i stanjenje sloja živčanih vlakana PNO (lat. papilla nervi optici). U ovom prospektivnom istraživanju 
ispitivali smo dolazi li kod bolesnika s POAG koji moraju primati bevacizumab do dodatnog stanjenja debljine RNFL (engl. 
retinal nerve fi ber layer). U istraživanje je bilo uključeno 60 bolesnika podijeljenih u dvije skupine. Prvu skupinu su činile 
oči bolesnika koji imaju eksudativnu SMD i POAG, a drugu oni koji imaju DME i POAG te su liječeni bevacizumabom. 
Kontrolnu skupinu činilo je drugo oko u koje nije apliciran bevacizumab. Kod svih bolesnika mjerila se debljina sloja živčanih 
vlakana PNO pomoću optičke koherentne tomografi je kroz godinu dana, a dobivene vrijednosti su uspoređene s kontrolnim 
skupinama te međusobno. Rezultati su pokazali da su nakon godinu dana sve skupine imale stanjenje RNFL, ali dok u prvoj 
skupini nije bilo statistički značajne razlike između liječenog i neliječenog oka, u drugoj skupini je ta razlika ipak bila sta-
tistički značajna. Uspoređujući ove dvije skupine bolesnika dobiveno je statistički veće stanjenje RNFL nakon godinu dana 
u drugoj skupini bolesnika (DME + POAG).
Ključne riječi: Intravitrealne injekcije; Vaskularni endotelni čimbenik rasta A; Bevacizumab; Retinalna degeneracija; Makular-
ni edem; Dijabetes melitus; Glaukom, primarni, otvorenog kuta; Hrvatska
